A 68-year-old woman with systemic sclerosis and interstitial lung disease presented with progressive cough and dyspnea. She was in respiratory distress, with a heart rate of 110 beats per minute, respiratory rate 35, and oxygen saturation 63% on ambient air, which improved to 94% with 15l of 100% oxygen by face mask. Lungs had diffuse crackles throughout. Lab results revealed hemoglobin of 7.2g/dL. Her chest xray showed multifocal bilateral airspace opacities ( Fig.1 ). She was intubated; subsequent bronchoscopy revealed progressively hemorrhagic lavage fluid ( Fig.2) indicative of diffuse alveolar hemorrhage (DAH). She was started on high-dose intravenous corticosteroid and cyclophosphamide. Due to ongoing DAH, bleeding was temporized with intravenous aminocaproic acid and intrabronchial activated factor VIIa (rFVIIa). 1 -3 Ultimately, she developed ventilator-associated pneumonia and died.
DAH is characterized by bleeding into the alveolar spaces from disruption of the alveolar-capillary barrier. 4 Cough, dyspnea and hemoptysis are common, although one-third of patients may not have hemoptysis. 5 DAH has a broad differential including ANCA-associated vasculitides, anti-GBM disease, lupus and rarely systemic sclerosis. 4, 6, 7 Treatment depends on the underlying cause, but in the setting of life-threatening DAH, intravenous aminocaproic acid and intrabronchial rFVIIa have been shown to temporize bleeding. Data on mortality benefit is lacking. 
